Cite
Discovery of PEGylated 6‑Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1R Inverse Agonists.
MLA
Zhang, Yue-Mei, et al. “Discovery of PEGylated 6‑Benzhydryl-4-Amino-Quinazolines as Peripherally Restricted CB1R Inverse Agonists.” ACS Medicinal Chemistry Letters, vol. 11, no. 12, Dec. 2020, pp. 2504–09. EBSCOhost, https://doi.org/10.1021/acsmedchemlett.0c00495.
APA
Zhang, Y.-M., Greco, M., Le Blanc, T., Lang, W., Kauffman, J., Masucci, J., Murray, W. V., Demarest, K., & Macielag, M. J. (2020). Discovery of PEGylated 6‑Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1R Inverse Agonists. ACS Medicinal Chemistry Letters, 11(12), 2504–2509. https://doi.org/10.1021/acsmedchemlett.0c00495
Chicago
Zhang, Yue-Mei, Michael Greco, Tonya Le Blanc, Wensheng Lang, Jack Kauffman, John Masucci, William V. Murray, Keith Demarest, and Mark Joseph Macielag. 2020. “Discovery of PEGylated 6‑Benzhydryl-4-Amino-Quinazolines as Peripherally Restricted CB1R Inverse Agonists.” ACS Medicinal Chemistry Letters 11 (12): 2504–9. doi:10.1021/acsmedchemlett.0c00495.